NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.
First Quarter 2010 Highlights:
- Revenue growth of 22% vs. Q1 09
- Test volume growth of 34% vs. Q1 09
- Launched MelanoSITE melanoma FISH test in February
- Amended credit facility to provide up to $5.0 million of working capital
Revenue for the first quarter 2010 was $8.4 million, a 22% increase over first quarter 2009 revenue of $6.9 million. Revenue increases were driven by significant growth in all key testing services. Requisitions increased by approximately 25% and test volume increased by 34% over first quarter 2009. After adjusting for the adverse impacts caused by the internalization of bladder cancer FISH testing by the Company's largest client beginning in mid 2009, revenue and test volume from all other clients grew by 42% and 54%, respectively.
The company continued to aggressively invest in growth initiatives. Sales and marketing expenses increased by $429,000, or 32%, driven by significant investments made throughout 2009 in the size of the sales force and in marketing capabilities. General and Administrative ("G&A") expenses increased by $561,000, or 24%, primarily as a result of additional management and information technology personnel, and due to approximately $200,000 of additional R&D expenses incurred to develop the Melanoma FISH test during the first quarter. Net loss for the quarter was ($750,000) or ($0.02)/share versus net income of $33,000 or $0.00/share in the first quarter 2009.
Doug VanOort, the Company's Chairman and CEO, commented, "We are pleased with our first quarter results. Despite the revenue impacts from adverse weather in the Northeast during the first two months, we finished the quarter with strong test volume and set a new monthly revenue record in March. We also made substantial progress towards achieving profitability in the quarter. Gross margins increased by 1.1% compared with the fourth quarter 2009 as a result of productivity gains in our operations. In addition, total selling, general and administrative ("SG&A") expenses decreased by over $400,000 compared with last quarter. We were also able to renegotiate our accounts receivable-based credit facility, and we now have up to $5.0 million of liquidity available through this facility."
Bob Gasparini, the Company's President and Chief Scientific Officer, stated, "The launch of our MelanoSITE melanoma FISH test in mid February was the most significant corporate event in the first quarter. We have now trained approximately 80 pathologists on how to use this new test and volumes are starting to grow. As we have discussed previously, we expect MelanoSITE test volumes to be modest until we can publish the results of our validation study in a peer reviewed journal, which we believe will occur later this year. So far, however, we have received great feedback from the doctors who are using it."
The Company also announced today that it expects revenue of approximately $8.8 - $9.2 million in the second quarter with a net loss of between $0.00 – ($0.02)/share.
Evo model set to transform synthetic biology and disease diagnosis